AZN - AstraZeneca PLC
LSE
->
Healthcare
->
Drug Manufacturers—General
Cambridge,
United Kingdom
AZN price evolution
AZN
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15567 | $7636 | $7832 | $8072 |
| Short term investments | $62 | $129 | $160 | $374 |
| Net receivables | $6842 | $6628 | $7386 | $6000 |
| Inventory | $4762 | $4278 | $4024 | $3683 |
| Total current assets | $27274 | $18735 | $19544 | $18166 |
| Long term investments | $1120 | $1060 | $1147 | $1215 |
| Property, plant & equipment | $9031 | $8849 | $8917 | $8360 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $46367 | $46191 | $47185 | $45946 |
| Total investments | ||||
| Total assets | $73641 | $64926 | $66729 | $64112 |
| Current liabilities | ||||
| Accounts payable | $17729 | $17370 | $15785 | $13406 |
| Deferred revenue | ||||
| Short long term debt | $2894 | $2258 | $2386 | $3585 |
| Total current liabilities | $22222 | $21513 | $20307 | $18942 |
| Long term debt | $24601 | $17874 | $17994 | $18754 |
| Total noncurrent liabilities | $35726 | $28967 | $30784 | $31552 |
| Total debt | ||||
| Total liabilities | $57965 | $50496 | $51107 | $51917 |
| Shareholders' equity | ||||
| Retained earnings | $7368 | $6126 | $7323 | $3915 |
| Other shareholder equity | $2050 | $2053 | $2040 | $3462 |
| Total shareholder equity | $15676 | $14430 | $15622 | $12195 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7832 | $5369 | $4831 | $3324 |
| Short term investments | $160 | $849 | $849 | $1230 |
| Net receivables | $5651 | $5181 | $4345 | $4275 |
| Inventory | $4024 | $3193 | $2890 | $3035 |
| Total current assets | $19544 | $15563 | $15591 | $13150 |
| Long term investments | $1147 | $1459 | $922 | $1036 |
| Property, plant & equipment | $8917 | $8335 | $7421 | $7615 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $47185 | $45814 | $45060 | $50204 |
| Total investments | ||||
| Total assets | $66729 | $61377 | $60651 | $63354 |
| Current liabilities | ||||
| Accounts payable | $2350 | $1774 | $1720 | $3611 |
| Deferred revenue | ||||
| Short long term debt | $2386 | $2010 | $1754 | $2247 |
| Total current liabilities | $20307 | $18117 | $16292 | $16383 |
| Long term debt | $17994 | $16217 | $17359 | $15560 |
| Total noncurrent liabilities | $30784 | $28664 | $30315 | $30329 |
| Total debt | ||||
| Total liabilities | $51107 | $48250 | $48183 | $48394 |
| Shareholders' equity | ||||
| Retained earnings | $7323 | $4858 | $7724 | $10250 |
| Other shareholder equity | $2040 | $3515 | $3617 | $3711 |
| Total shareholder equity | $15622 | $13127 | $12468 | $14960 |
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8220 | $7320 | $7410 | $6578 |
| Cost of revenue | $2193 | $1920 | $1515 | $1390 |
| Gross Profit | $6027 | $5400 | $5895 | $5188 |
| Operating activities | ||||
| Research & development | $1801 | $1638 | $1984 | $1453 |
| Selling, general & administrative | $2574 | $2498 | $2627 | $2270 |
| Total operating expenses | $7093 | $5425 | $5923 | $5407 |
| Operating income | $1127 | $1895 | $1487 | $1171 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $214 | $46 | $162 | $202 |
| Interest expense | ||||
| Net income | ||||
| Net income | $550 | $1561 | $1012 | $648 |
| Income (for common shares) | $550 | $1561 | $1012 | $648 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $26617 | $24384 | $22090 | $22465 |
| Cost of revenue | $5270 | $4824 | $4213 | $4137 |
| Gross Profit | $21347 | $19560 | $17877 | $18328 |
| Operating activities | ||||
| Research & development | $6094 | $5320 | $5266 | $5412 |
| Selling, general & administrative | $9338 | $8964 | $8479 | $7573 |
| Total operating expenses | $21455 | $21460 | $18703 | $18788 |
| Operating income | $5162 | $2924 | $3387 | $3677 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $772 | $321 | -$57 | -$25 |
| Interest expense | -$161 | |||
| Net income | ||||
| Net income | $3196 | $1335 | $2155 | $3001 |
| Income (for common shares) | $3196 | $1335 | $2155 | $3001 |
| (in millions $) | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 | 30 Sep 2020 |
|---|---|---|---|---|
| Net income | $764 | $1608 | $1167 | $853 |
| Operating activities | ||||
| Depreciation | $753 | $797 | $797 | $801 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $892 | $1934 | $1798 | $1822 |
| Investing activities | ||||
| Capital expenditures | -$353 | -$469 | -$548 | -$705 |
| Investments | ||||
| Total cash flows from investing | -$236 | $555 | $138 | -$580 |
| Financing activities | ||||
| Dividends paid | -$2469 | -$1174 | ||
| Sale and purchase of stock | $4 | $5 | $19 | $2 |
| Net borrowings | $7284 | -$244 | -$2229 | $2423 |
| Total cash flows from financing | $7289 | -$2731 | -$2210 | $1243 |
| Effect of exchange rate | $15 | -$67 | $26 | $4 |
| Change in cash and equivalents | $7960 | -$309 | -$248 | $2489 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | $3916 | $1548 | $1993 | $2227 |
| Operating activities | ||||
| Depreciation | $3149 | $3762 | $3753 | $3036 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $4799 | $2969 | $2618 | $3578 |
| Investing activities | ||||
| Capital expenditures | -$2606 | -$2460 | -$1371 | -$1620 |
| Investments | ||||
| Total cash flows from investing | -$285 | -$657 | $963 | -$2328 |
| Financing activities | ||||
| Dividends paid | -$3572 | -$3592 | -$3484 | -$3519 |
| Sale and purchase of stock | $30 | $3525 | $34 | $43 |
| Net borrowings | $1440 | -$1702 | $1473 | $560 |
| Total cash flows from financing | -$2203 | -$1765 | -$2044 | -$2936 |
| Effect of exchange rate | $12 | $5 | -$38 | -$66 |
| Change in cash and equivalents | $2323 | $552 | $1499 | -$1752 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $29.53B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $3.77B |
| Revenue Q/Q | 31.00% |
| Revenue Y/Y | 14.90% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | 5.60% |
| ROE | 26.04% |
| Debt/Equity | 3.27 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.23 |
| Quick ratio | 1.01 |